CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin αIIbβ3 in platelets
- 1 September 2008
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 112 (5) , 1696-1703
- https://doi.org/10.1182/blood-2008-02-139733
Abstract
Second messenger-mediated inside-out activation of integrin αIIbβ3 is a key step in platelet aggregation. We recently showed strongly impaired but not absent αIIbβ3-mediated aggregation of CalDAG-GEFI–deficient platelets activated with various agonists. Here we further evaluated the roles of CalDAG-GEFI and protein kinase C (PKC) for αIIbβ3 activation in platelets activated with a PAR4 receptor–specific agonist, GYPGKF (PAR4p). Compared with wild-type controls, platelets treated with the PKC inhibitor Ro31-8220 or CalDAG-GEFI–deficient platelets showed a marked defect in aggregation at low (< 1mM PAR4p) but not high PAR4p concentrations. Blocking of PKC function in CalDAG-GEFI–deficient platelets, how-ever, strongly decreased aggregation at all PAR4p concentrations, demonstrating that CalDAG-GEFI and PKC represent separate, but synergizing, pathways important for αIIbβ3 activation. PAR4p-induced aggregation in the absence of CalDAG-GEFI required cosignaling through the Gαi-coupled receptor for ADP, P2Y12. Independent roles for CalDAG-GEFI and PKC/Gαi signaling were also observed for PAR4p-induced activation of the small GTPase Rap1, with CalDAG-GEFI mediating the rapid but reversible activation of this small GTPase. In summary, our study identifies CalDAG-GEFI and PKC as independent pathways leading to Rap1 and αIIbβ3 activation in mouse platelets activated through the PAR4 receptor.Keywords
This publication has 52 references indexed in Scilit:
- A LAD-III syndrome is associated with defective expression of the Rap-1 activator CalDAG-GEFI in lymphocytes, neutrophils, and plateletsThe Journal of Experimental Medicine, 2007
- Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type IIIJournal of Clinical Investigation, 2007
- PAR1, but Not PAR4, Activates Human Platelets through a Gi/o/Phosphoinositide-3 Kinase Signaling AxisMolecular Pharmacology, 2007
- An essential role for RasGRP1 in mast cell function and IgE-mediated allergic responseThe Journal of Experimental Medicine, 2006
- Natural history and early diagnosis of LAD-1/variant syndromeBlood, 2006
- PAR4, but Not PAR1, Signals Human Platelet Aggregation via Ca2+ Mobilization and Synergistic P2Y12 Receptor ActivationJournal of Biological Chemistry, 2006
- Epac1-Rap1 signaling regulates monocyte adhesion and chemotaxisJournal of Leukocyte Biology, 2006
- RasGRP3 mediates phorbol ester-induced, protein kinase C-independent exocytosisBiochemical and Biophysical Research Communications, 2005
- Molecular Basis of Platelet Granule SecretionArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Impaired activation of murine platelets lacking Gαi2Journal of Clinical Investigation, 2001